-

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common stock. The dividend is payable on March 28, 2024, to stockholders of record at the close of business on March 15, 2024. Future dividends will be subject to Board approval.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Contacts

Investors:
Jacquie Ross, CFA
investor_relations@gilead.com

Media:
Ashleigh Koss
public_affairs@gilead.com

Industry:

Gilead Sciences, Inc.

NASDAQ:GILD
Release Versions
English
Hashtags
#GILD
#GILDDividend
#Gilead
#GileadQuarterlyDividend
#GileadSciences

Contacts

Investors:
Jacquie Ross, CFA
investor_relations@gilead.com

Media:
Ashleigh Koss
public_affairs@gilead.com

Social Media Profiles
Gilead Sciences Facebook
Gilead Sciences Instagram
Gilead Sciences LinkedIn
Gilead Sciences YouTube
More News From Gilead Sciences, Inc.

PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead’s twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. Bringing together th...

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

FOSTER CITY, Calif. & MUNICH--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), building on Gilead’s oncology pipeline, focused on addressing areas of high unmet need. The acquisition significantly expands Gilead’s ADC capabilities by adding next-generation assets and platforms designed t...

Gilead Extends Tender Offer to Acquire Arcellx

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right (CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subjec...
Back to Newsroom